5 Key Takeaways
-
1
Point-of-care STI tests provide results near the site of care, typically within minutes to an hour, enabling clinical decisions during the same visit.
-
2
FDA-cleared, CLIA-waived molecular assays can detect chlamydia and gonorrhea in about 20 minutes, with accuracy approaching laboratory-based testing.
-
3
Same-visit results can reduce dependence on follow-up, which is especially important for people facing barriers to care or at increased risk of being lost to follow-up.
-
4
Point-of-care testing may reduce empiric treatment and unnecessary antibiotic exposure, while supporting antimicrobial stewardship.
-
5
Implementation challenges include cost, operational complexity, specimen-type restrictions, workflow demands, and the need for staff training and quality oversight.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

About the Author(s)
Nikolina Babic
Nikolina Babic is Board-certified clinical chemist and Professor of Pathology and Laboratory Medicine, Medical University of South Carolina.
Sheldon Campbell
Sheldon Campbell is Professor of Laboratory Medicine, Yale School of Medicine, and Director of Clinical Laboratories, VA Connecticut Healthcare System.
Kate Crawford
Kate Crawford is Acting Assistant Professor, Department of Laboratory Medicine and Pathology, University of Washington.